Business & Regulation

A quick look at reactions across the US to Biden’s Build Back Better bill.

Environmental, social, and governance (ESG) plans should be an integral part of any company that aims to thrive in today’s society.

Meet Ori Biotech’s Jason Foster. How did he transition to advanced therapy, and why did he end up in the UK?

Four courageous marketer-knights weigh in on what it takes to tilt against the social media windmills of pharma’s digital content kingdom.

Charlie Badham of 4D Pharma tells us his approach to social media in an age of outrage and tonal mixups.

Mike Rea of IDEA Pharma speaks frankly on the mud fights, echo chambers, and risks at play in the virtual forums of social media in 2021.

The EMA has given the nod to Ronapreve and Regkirona, two monoclonal antibody treatments for COVID-19.

After a madcap back and forth between leading and dissenting Democrats, Biden’s drug pricing reform plans have reached a compromised final form.

Stating an intention to be ready to win in any biowarzone, the US military has commissioned Dynavax to develop a vaccine for the plague.

The FDA has approved just three biosimilars in 2021 – but the approvals could shake up the field as discussions around interchangeability intensify.